Biocartis

Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample

in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

09/06/2026

📢 𝗣𝗥𝗘𝗦𝗦 𝗡𝗘𝗪𝗦: 𝗕𝗶𝗼𝗰𝗮𝗿𝘁𝗶𝘀 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗖𝗶𝘁𝘆 𝗼𝗳 𝗛𝗼𝗽𝗲 𝘁𝗼 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗥𝗮𝗽𝗶𝗱 𝗚𝗲𝗻𝗲 𝗦𝗶𝗴𝗻𝗮𝘁𝘂𝗿𝗲 𝗧𝗲𝘀𝘁 𝗳𝗼𝗿 𝗘𝗮𝗿𝗹𝘆 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗣𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿
We're excited to announce that we have entered into an agreement with City of Hope to explore the development of a 𝗿𝗮𝗽𝗶𝗱, 𝗯𝗹𝗼𝗼𝗱-𝗯𝗮𝘀𝗲𝗱, 𝘀𝗮𝗺𝗽𝗹𝗲-𝘁𝗼-𝗮𝗻𝘀𝘄𝗲𝗿 𝗴𝗲𝗻𝗲 𝘀𝗶𝗴𝗻𝗮𝘁𝘂𝗿𝗲 𝘁𝗲𝘀𝘁 𝗳𝗼𝗿 𝗲𝗮𝗿𝗹𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗽𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗰𝗮𝗻𝗰𝗲𝗿. Under the agreement, Biocartis has secured an option to license key patents and related know-how from City of Hope* to accelerate test development on the Idylla™ Platform.

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: https://lnkd.in/ettYgXtg

𝘛𝘩𝘦 𝘵𝘦𝘴𝘵 𝘪𝘯 𝘪𝘴 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘶𝘴𝘦.
* 𝘜𝘯𝘥𝘦𝘳 𝘵𝘩𝘦 𝘵𝘦𝘳𝘮𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘰𝘱𝘵𝘪𝘰𝘯 𝘢𝘨𝘳𝘦𝘦𝘮𝘦𝘯𝘵, 𝘊𝘪𝘵𝘺 𝘰𝘧 𝘏𝘰𝘱𝘦 𝘪𝘴 𝘦𝘯𝘵𝘪𝘵𝘭𝘦𝘥 𝘵𝘰 𝘢𝘯 𝘰𝘱𝘵𝘪𝘰𝘯 𝘧𝘦𝘦 𝘱𝘢𝘺𝘮𝘦𝘯𝘵.

09/06/2026

🌸☀️𝐒𝐩𝐫𝐢𝐧𝐠 𝐜𝐥𝐞𝐚𝐧𝐢𝐧𝐠 𝐢𝐬𝐧’𝐭 𝐣𝐮𝐬𝐭 𝐟𝐨𝐫 𝐲𝐨𝐮𝐫 𝐡𝐨𝐦𝐞, 𝐲𝐨𝐮𝐫 𝐥𝐚𝐛 𝐝𝐞𝐬𝐞𝐫𝐯𝐞𝐬 𝐚 𝐫𝐞𝐟𝐫𝐞𝐬𝐡 𝐭𝐨𝐨!

Is your lab still dealing with cluttered workstations and complex workflows?
Declutter your lab. Simplify your workflow. THINK IDYLLA™:
✅ < 3 minutes hands-on time
✅ compact & fully automated system
✅ molecular biomarker results in only 3 hours

🔗 Get more info now: https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=meet-idylla

07/06/2026

🎗️ Today, on National Cancer Survivors Day®, we celebrate the strength, resilience, and stories of millions who have faced cancer — and have overcome it.

At Biocartis, we are proud to support this journey with Idylla™, our fully automated platform that delivers fast and accurate molecular insights — empowering informed and personalized treatment decisions at the heart of cancer survival.
🔬 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐡𝐨𝐰 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐢𝐬 𝐡𝐞𝐥𝐩𝐢𝐧𝐠 𝐚𝐝𝐯𝐚𝐧𝐜𝐞 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲: https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=idylla-platform

04/06/2026

𝗝𝗢𝗜𝗡 𝗢𝗨𝗥 𝗙𝗥𝗘𝗘 𝗪𝗘𝗕𝗜𝗡𝗔𝗥: 𝗖𝗥𝗖 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗶𝗻 𝟮𝟬𝟮𝟲: 𝗪𝗵𝗮𝘁'𝘀 𝗡𝗲𝘄, 𝗪𝗵𝗮𝘁'𝘀 𝗡𝗲𝘅𝘁? 𝗔𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝗶𝘀𝘁'𝘀 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲 𝗼𝗻 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗧𝗲𝘀𝘁𝗶𝗻𝗴
📅 Thursday 25 June, 13:00 (CEST)
🎤 Professor Jenny Seligmann (Consultant Medical Oncologist, Leeds Teaching Hospitals NHS Trust & Professor of Gastrointestinal Oncology, University of Leeds)
📍 Online, registration required

𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
- The key changes in ESMO mCRC guidelines
- The role of dual IHC/molecular testing for immunotherapy eligibility
- The emerging testing strategies in early-stage disease

👉 𝗦𝗮𝘃𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁 𝗻𝗼𝘄: https://register.gotowebinar.com/register/7831863561846158940
Can’t join live? By registering, you will get access to the recording afterwards.

02/06/2026

𝟏 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦. 𝟗𝟓+ 𝐜𝐨𝐮𝐧𝐭𝐫𝐢𝐞𝐬. 𝐂𝐨𝐮𝐧𝐭𝐥𝐞𝐬𝐬 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐞𝐝.
The Idylla™ Platform empowers pathologists and oncologists worldwide with fast, reliable molecular biomarker testing. Every day, it helps them make confident, data-driven decisions.

𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 👉 https://www.biocartis.com/en/meet-idylla/idylla-platform?utm_source=facebook&utm_medium=social&utm_campaign=idylla-platform

Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries

01/06/2026

𝗛𝗮𝘃𝗶𝗻𝗴 𝗮 𝗯𝗹𝗮𝘀𝘁 𝗮𝘁 𝗔𝗦𝗖𝗢!
📍Booth 18152 | 🗺️ Chicago, IL, US

Join us at booth 𝟭𝟴𝟭𝟱𝟮 to discover how the 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 can deliver molecular biomarker results in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀⏱️ Because securing targeted answers shouldn't require waiting on NGS....
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 👉 https://www.biocartis.com/en-US/meet-idylla

28/05/2026

🚀 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗶𝘀 𝗻𝗼𝘄 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿𝗲𝗱 𝗶𝗻 𝗨𝗸𝗿𝗮𝗶𝗻𝗲
We are proud to share that the Idylla™ Platform is now successfully registered in Ukraine. In a healthcare environment facing severe disruption, 𝗳𝗮𝘀𝘁 𝗮𝗻𝗱 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗰𝗮𝗻 𝗺𝗮𝗸𝗲 𝗮 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 for patients and HCPs navigating a cancer diagnosis — enabling faster patient management decisions when time matters most⏱️

At Biocartis, we remain committed to expanding access to accurate molecular diagnostics worldwide 🎗️

🤝 𝗠𝗲𝗲𝘁 𝗼𝘂𝗿 𝗨𝗸𝗿𝗮𝗶𝗻𝗶𝗮𝗻 𝗱𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗼𝗿 BIONIX LAB:
https://lnkd.in/ePjT4ufS

👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺: https://lnkd.in/g_7rKdP

27/05/2026

𝐒𝐩𝐫𝐢𝐧𝐠 𝐭𝐢𝐦𝐞! 𝐓𝐢𝐦𝐞 𝐭𝐨 𝐠𝐞𝐭 𝐭𝐡𝐞 𝐬𝐮𝐧𝐬𝐜𝐫𝐞𝐞𝐧 𝐨𝐮𝐭☀️
May is Melanoma & Skin Cancer Awareness Month, a month in which we take time to raise awareness on preventing and treating skin cancer and melanoma 🖤

Biocartis offers the 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐁𝐑𝐀𝐅 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐓𝐞𝐬𝐭* for patients with advanced melanoma. This Test offers 𝐟𝐮𝐥𝐥𝐲 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝟕 𝐁𝐑𝐀𝐅 𝐦𝐮𝐭𝐚𝐭𝐢𝐨𝐧𝐬 in codon 600 directly from 𝟏 𝐅𝐅𝐏𝐄 𝐭𝐢𝐬𝐬𝐮𝐞 𝐬𝐞𝐜𝐭𝐢𝐨𝐧 👉 https://www.biocartis.com/en/meet-idylla/idylla-oncology-tests/idylla-braf-mutation-test?utm_source=facebook&utm_medium=social&utm_campaign=idylla-braf-mutation-test

*CE-marked in Europe in compliance with the EU IVD Directive 98/79/EC. For Research Use Only (RUO), not for use in diagnostic procedures, in the US.
The Skin Cancer Foundation

25/05/2026

Revolutionize your CRC diagnostics with Idylla™ 🏆

⏱️Speed up your therapy decisions and alleviate patient anxiety*!

Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, with results in only three hours. Ensure they receive the most effective treatment without delay.

👉 Read morehttps://www.biocartis.com/sites/default/files/2026-03/CRC%20Oncologist%20-%20Leaflet%20-%20Mar2026.pdf

Your patients, our priority. Guiding them to the right therapy within hours ⚡

*Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.
The content of this post is only applicable to Idylla™ KRAS & NRAS-BRAF Mutation Tests and Idylla™ MSI & CDx MSI Tests which are CE-marked in Europe; Idylla™ MSI Test which is cleared in the US under K211181 for Lynch Syndrome; and Idylla™ CDx MSI Test which is approved in the US under P250005. Idylla™ KRAS & NRAS-BRAF Mutation Assays are for Research Use Only (RUO), not for use in diagnostic procedures, in the US.

22/05/2026

𝗪𝗲'𝗿𝗲 𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝗔𝗦𝗖𝗢! 🚀
📅 29 May - 2 June |📍Booth 18152 | 🗺️ Chicago, IL, US

Join us at booth 𝟭𝟴𝟭𝟱𝟮 to discover how the 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 can deliver molecular biomarker results in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀⏱️Because securing targeted answers shouldn't require waiting on NGS....

𝗟𝗲𝘁'𝘀 𝗰𝗼𝗻𝗻𝗲𝗰𝘁 𝗮𝘁 𝗔𝗦𝗖𝗢 👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://lnkd.in/eSx8X2ZV

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

http://www.biocartis.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.